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Epstein-Barr virus nuclear antigen EBNA1, the one viral protein uniformly expressed in nasopharyngeal
carcinoma (NPC), represents a prime target for T-cell-based immunotherapy. However, little is known about
the EBNA1 epitopes, particularly CD4 epitopes, presented by HLA alleles in Chinese people, the group at
highest risk for NPC. We analyzed the CD4 T-cell responses to EBNA1 in 78 healthy Chinese donors and
found marked focusing on a small number of epitopes in the EBNA1 C-terminal region, including a DP5-
restricted epitope that was recognized by almost half of the donors tested and elicited responses able to
recognize EBNA1-expressing, DP5-positive target cells.
Undifferentiated nasopharyngeal carcinoma (NPC), an un-
usually prevalent tumor in Southeast Asian and particularly
Chinese populations, is consistently Epstein-Barr virus (EBV)
positive and expresses a subset of EBV latent proteins. These
include the nuclear antigen EBNA1, the latent membrane pro-
tein LMP2 in most cases, and in some cases LMP1 (12). A
detailed knowledge of both CD4 and CD8 T-cell responses
to these antigens is needed if one is to exploit such responses
for immunotherapeutic use (1, 7, 15). While there has been
extensive work on CD8 T-cell responses in that regard (4),
CD4-based studies have focused almost exclusively on Cauca-
sian donors (3, 6, 8, 10, 11, 14, 20) and little is known about
responses restricted through the different array of HLA II
alleles found in the Chinese population. Here we focus on CD4
responses to EBNA1, the only viral protein known to be ex-
pressed in all NPC tumors and one which proves to be a rich
source of CD4 epitopes.
ELISPOT assay mapping of CD4 epitope regions. Eighty-
one peptides (20-mers overlapping by 15 residues) were syn-
thesized according to the EBNA1 sequence common to 27/31
Chinese EBV strains, of which the NPC 15 (CKL) virus strain
is the prototype (9). On the basis of published protocols (6),
these peptides were tested individually in enzyme-linked im-
munospot (ELISPOT) assays of gamma interferon (IFN-)
release with peripheral blood mononuclear cells (PBMCs,
CD8 T cell depleted) obtained with informed consent from
healthy, EBV-seropositive Chinese donors resident in Hong
Kong, an area with a high incidence of NPC. Figure 1 shows
representative results from four responsive donors, HK 201,
HK 215, HK 263, and HK 280, to illustrate the low back-
grounds (0 to 10 spots/well) usually seen and the clear focusing
of responses mostly on adjacent sets of two or three overlap-
ping peptides in specific regions of the molecule. Overall, 50/78
donors tested in repeat assays showed reproducible responses
to particular peptides.
On this basis, we identified 10 distinct epitope regions in the
Chinese EBNA1 sequence. These are located on a linear map
of the EBNA1 protein (Fig. 2, right) where the filled horizontal
bars represent the percentages of donors responding to each
epitope region. Alongside (Fig. 2, left) are shown the corre-
sponding data from 37 healthy seropositive Caucasian donors
tested against the standard B95.8 EBNA1 peptide panel (6;
unpublished data). In both cases, CD4 epitopes are concen-
trated within the C-terminal half of the molecule. However,
compared to those of Caucasians, the EBNA1 responses of
Chinese donors are focused on a smaller number of epitope
regions, with correspondingly higher percentages of donors
responding to individual regions. In particular, EBNA1 pep-
tides 67 and 68 were recognized by 47% (37/78) of the Chinese
donors tested, a far higher frequency than that seen for any
Caucasian donor response.
Epitope definition by CD4 T-cell cloning. Four epitope
regions, represented by Chinese EBNA1 peptides 48 and 49,
50 and 51, 56 and 57, and 67 and 68, were selected for detailed
analysis. On the basis of previously published protocols (8),
PBMCs from selected donors were stimulated in vitro with
relevant peptide pairs and cloned on day 7 at limiting dilution
(0.3 cell/well) on autologous CKL virus-transformed B-lym-
phoblastoid cell line (LCL) feeders, and clones reactive to the
stimulating peptide pair were identified by specific IFN- re-
lease in an enzyme-linked immunosorbent assay. Such clones
were assayed on the autologous LCL loaded with serial dilu-
tions of individual peptides from the epitope region in order to
identify the optimal 20-mer epitope. Representative results are
* Corresponding author. Mailing address: Cancer Research UK In-
stitute for Cancer Studies, University of Birmingham, Vincent Drive,
Birmingham, United Kingdom B15 2TT. Phone: 44-121-414-4492. Fax:
44-121-414-4486. E-mail: A.B.Rickinson@bham.ac.uk.
† C.W.T. and X.L. contributed equally to this work.
8263
 at UNIV O
F BIRM
ING
HAM
 on Septem
ber 29, 2008 
jvi.asm.org
D
ow
nloaded from
 
shown in Fig. 3A. Clones from donor HK 215 against the
peptide 48 and 49 region recognized peptide 49 but, surpris-
ingly, not peptide 48 even though both peptides had elicited
equally strong responses in the original ELISPOT assays.
Clones against the other epitope regions showed recognition of
two or more adjacent peptides but consistently identified one
of those peptides most efficiently, i.e., peptide 50 for clones
from donor HK 228, peptide 56 for clones from donor HK 233,
and peptide 67 for clones from two donors, HK 215 and
HK 228 (data not shown). Note also that these EBNA1
epitope-specific clones all showed functional avidities (defined
as the minimum peptide concentration required for 50%
monoclonal IFN- release) within the 10- to 100-nM range,
similar to those seen for most EBNA1-specific reactivities iso-
lated from Caucasian donors (8). Moreover, they were also
confirmed as antigen specific since they recognized autologous
target cells expressing a class II-targeted EBNA1 protein ex-
pressed from a recombinant vaccinia virus vector (17; data not
shown).
HLA class II restriction of epitope-specific responses. Fig-
ure 3B shows the restriction data obtained from these clones in
two types of assay. As previously described (8), these used (i)
individual HLA-DP-, -DQ-, or -DR-specific monoclonal anti-
bodies (MAbs) to block the recognition of autologous peptide-
loaded cells and (ii) allogeneic target cells of known HLA type
as peptide-presenting cells. Both the peptide 49-specific and
peptide 56-specific clones proved to be HLA-DR restricted by
blocking, but the precise alleles could not be identified by using
the allogeneic targets available at that time. We therefore
HLA typed 47 donors from the original panel; this revealed
strong correlations between HLA-DR51 positivity and respon-
siveness to peptide 49 and between HLA-DR11 positivity and
responsiveness to peptide 56, suggesting that these were the
likely restricting alleles. With regard to peptide 50, the MAb
blocking and allogeneic LCL assays suggested that this was
HLA-DQ7 restricted and, indeed, all five donors showing this
response in ELISPOT assays were DQ7 positive; however,
another 15 DQ7-positive individuals showed no response, sug-
gesting that this is not a consistently immunodominant epitope.
Most importantly, the peptide 67 response proved to be HLA-
DP5 restricted. This immediately suggested why it was seen so
frequently in the ELISPOT assays, since HLA-DP5 is carried
by50% of Chinese people (19) and, indeed, all responders to
this allele who were HLA typed proved to be DP5 positive.
FIG. 1. Results of IFN- ELISPOT assays using CD8-depleted
PBMCs from healthy Chinese donors exposed to individual CKL strain
EBNA1 peptides (1 to 81) or assayed in the absence of peptide as a
control (c). Results from four different donors are shown as numbers
of spot-forming cells per 106 CD8-depleted PBMCs tested. Note that
responses occasionally mapped to a single peptide (e.g., HK 201,
peptide 64) but usually mapped to two or three adjacent peptides (e.g.,
HK 201, peptides 41 and 42 and peptides 50 and 51; HK 215, peptides
48 and 49 and peptides 66, 67, and 68). Where there was recognition
of four or five adjacent peptides, cloning frequently revealed coresi-
dent responses to two separate epitopes.
FIG. 2. Locations of CD4 epitope regions, identified by peptide
number, on a linear map of the EBNA1 protein (with the position of
the internal glycine-alanine repeat domain also shown). (Right) Sum-
mary of data from 78 healthy Chinese donors screened by using the
CKL strain EBNA1 peptide panel. (Left) Summary of data from 37
healthy Caucasian donors from the United Kingdom who were
screened by using the B95.8 strain EBNA1 peptide panel. In each case,
the filled bars indicate the percentages of donors tested who responded
to these particular epitope regions.
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FIG. 3. Functional analysis of CD4 T-cell clones established from selected healthy Chinese donors by stimulating PBMCs with CKL strain EBNA1
peptide pair 48 and 49, 49 and 50, 56 and 57, or 67 and 68. (A) Identifying the optimal 20-mer epitope. Clones were stimulated with the autologous LCL
preloaded with limiting concentrations of individual peptides from the epitope region; recognition was assayed as IFN- release by enzyme-linked
immunosorbent assay. neg, negative. (B) Identifying HLA class II restriction. (Top) Clones were stimulated with the autologous LCL preloaded with a
just-optimal concentration of the epitope peptide in the presence of MAbs to HLA-DP, -DQ, or -DR. (Bottom) Clones were stimulated with the
autologous LCL or with an HLA-typed allogeneic LCL preloaded with a concentration of peptide similar to that above; relevant HLA class II alleles
shared between the LCL and donor T cells are shown. Results are expressed as in panel A. (C) Recognizing unmanipulated LCL. Clones seeded at
different cell numbers were stimulated with a standard number of cells of an autologous LCL (Aut) or an allogeneic HLA-mismatched LCL (Mis), either
alone or after loading with an optimal concentration of epitope peptide, and recognition was assayed as above.
TABLE 1. Summary of EBNA1 epitope responses
EBNA1
peptide no.
Amino acid
coordinates Epitope sequence
a No. of
respondersb
Restriction
element
% LCL
recognitione
41/42 434–458 IEQGPTDDPGEGPSTGPRGQGDGGR 2/43 NDc ND
49 474–493 SNPKFENIAEGLRVLLARSH 16/78 DR51 0.2
50 479–498 ENIAEGLRVLLARSHVERTT 5/43 DQ7 0.2
54/55 499–523 EEGNWVAGVFVYGGSKTSLYNLRRG 4/78 ND ND
56 509–528 VYGGSKTSLYNLRRGIALAV 11/78 DR11d 2
58/59 519–543 NLRRGIALAVPQCRITPLSRLPFGM 16/78 ND ND
64 549–568 PQPGPLRESIVCYFMVFLQT 1/43 ND ND
65/66 554–578 LRESIVCYFMVFLQTHIFAEVLKDA 14/78 ND ND
67 564–583 VFLQTHIFAEVLKDAIKDL 34/78 DP5 1
72/73 589–613 PTCNIKVTVCSFDDGVDLPPWFPPM 1/43 ND ND
a Amino acid changes in CKL strain EBNA1 relative to B95.8 EBNA1 are underlined.
b Note that of the 78 donors used, 43 were tested on all 81 EBNA1 peptides and a further 35 were tested on a limited panel of peptides that did not include peptide
41, 42, 50, 64, 72, or 73.
c ND, not determined.
d DR-restricted responses where the restricting allele is inferred to be DR51 and DR11 from the HLA type of epitope-responsive donors.
e IFN- levels from CD4 T cells challenged with the autologous LCL are expressed as a percentage of the levels seen on challenge with the same LCL optimally
loaded with epitope peptide.
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CD4 T-cell recognition of latently infected cells. Interest in
CD4 T-cell responses to EBV latent proteins reflects not just
their likely importance in the maintenance of effective CD8
T-cell surveillance (2, 13, 16) but also their possible role as
direct effectors capable of recognizing latently infected cells
that, like NPC tumors (5, 18), express HLA class II molecules.
To investigate this latter point, we used published protocols (8)
to assay the EBNA1-specific clones for recognition of autolo-
gous LCL targets. Specific recognition could not be detected
with clones to peptide 49 or 50 (data not shown). However,
clones to peptides 56 and 67 clearly did recognize the autolo-
gous LCL, with recognition titrating against T-cell input; for
these clones, levels of IFN- produced in response to the
autologous LCL (Fig. 3C, open bars, LCL alone) were around
2% and 1%, respectively, of those produced in response to the
same target cells optimally loaded with epitope peptide (Fig.
3C, filled bars, LCL  peptide).
Table 1 summarizes the essential data from the present
study. We conclude that most healthy Chinese donors possess
a strong CD4 T-cell memory for EBNA1; that responses are
focused on a small number of C-terminal EBNA1 epitopes,
including a DP5-restricted epitope seen by almost 50% of the
donors tested; and that some of the above responses (including
that to the DP5 epitope) have the potential to directly recog-
nize a latently infected HLA II-positive LCL. These findings
will help in both the design and testing of immunotherapeutic
strategies targeting NPC, whether based on vaccines to stimu-
late the patient’s own responses (7, 17) or on the adoptive
transfer of in vitro-expanded T-cell populations (1, 15).
This work was supported by Cancer Research UK, by the Hong
Kong Cancer Fund, and by the Royal Society, London.
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